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ABSTRACT
Aim of study. To evaluate the rate and factors predicting seizure remission in a large cohort of patients with epilepsy.
Materials and methods. Patients with epilepsy treated at a university epilepsy clinic were included in this study. The following 
information was collected by means of a structured questionnaire: age, sex, age at onset of epilepsy, aetiology of epilepsy, the 
presence of intellectual disability, duration and type of epilepsy, frequency of seizures, treatment of epilepsy, and mechanism 
of action of antiepileptic drugs (AEDs).
Results. A total of 530 adult patients participated in this study (mean age ± standard deviation: 36.1 ± 12.6 years). Of these, 
327 (61.7%) were female, and 364 (68.7%) patients had focal epilepsy. Twelve-month seizure freedom was achieved in 246 
(46.4%) patients. Logistic regression revealed several independent predictors of seizure freedom: younger age (odds ratio (OR) 
= 0.98; p = 0.037), male sex (OR = 1.54; p = 0.050), generalised epilepsy (OR = 1.61; p = 0.052), lower number of prescribed AEDs 
(OR = 0.22; p = 0.001), and taking a combination of valproate and lamotrigine (OR = 2.51; p = 0.024).
Conclusions. Most patients with epilepsy enter remission on monotherapy with their first or second AED. However, a substantial 
proportion of patients may benefit from combination therapy including valproate and lamotrigine polytherapy.
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Introduction
Epilepsy, with a prevalence of active disease of 6.38 per 
1,000 persons, is one of the most common neurological 
disorders [1]. Although nondrug therapies such as surgery, 
implantable devices, or a ketogenic diet are highly effective 
in some cases, for the vast majority of patients antiepileptic 
drugs (AEDs) are the mainstay of treatment. Currently used 
AEDs suppress the occurrence of seizures; however, they do 
not possess antiepileptogenic or disease-modifying activity. 
As a result, patients with epilepsy require long-term, or even 
lifelong, treatment with AEDs. Despite the development and 
introduction of many new AEDs with a differing mechanism 
of action (MOA) over the last two decades, the probability of 
achieving seizure freedom has not significantly increased [2, 3]. 
The correct classification of the type of seizure/epilepsy 
and the syndrome is indispensable for the appropriate man-
agement and prognosis. The International League Against 
Epilepsy (ILAE) recently released two position papers of its 
Commission for Classification and Terminology. These papers 
facilitate the classification of seizures and epilepsies, and 
therefore the choice of an adequate AED [4, 5]. Geographical 
and socioeconomic factors (i.e. specific aetiologies of epilepsy, 
ethnicity, availability of AEDs, and access to specialised ep-
ilepsy centres) can influence the outcome of epilepsy. Thus, 
each group of the population should have its own data on the 
treatment and outcome of epilepsy. Taking these points into 
consideration, we decided to study the treatment outcome in 
a large cohort of Polish adult patients with epilepsy.
Materials and methods
This was a retrospective study. Patients with epilepsy who 
were seen at the university epilepsy outpatient clinic between 
1 January, 2015 and 31 December, 2019 were identified from 
the electronic database. We included patients who were seen 
by one of the authors (MB) with a minimum period of obser-
vation and treatment of 12 months, and who had at least three 
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visits during the study period. Epilepsy was diagnosed accord-
ing to the ILAE’s practical clinical definition of epilepsy [6]. The 
following information was collected by means of a structured 
questionnaire: age, sex, age at onset of epilepsy, aetiology of 
epilepsy, duration and type of epilepsy, frequency of seizures, 
the presence of intellectual disability, AEDs treatment, and the 
MOA of the AEDs. Seizure types were classified according to 
the position paper of the ILAE’s Commission for Classification 
and Terminology [5]. Epilepsies were divided into four types: 
focal, generalised, combined (generalised and focal), and un-
known.  The aetiology of epilepsy was categorised as structural/
infectious, genetic or presumed genetic, or unknown [4].
The exclusion criteria were as follows: (a) no pharma-
cological treatment for epilepsy; (b) underlying progressive 
neurological or systemic disorder (mainly neoplasms); (c) 
coexistence of psychogenic nonepileptic seizures; and (d) non-
drug treatment i.e. epilepsy surgery, deep brain stimulation, 
or vagus nerve stimulation. Seizure freedom was defined as 
a patient experiencing no seizures in the past ≥ 12 months [7].
The study protocol was approved by the university’s 
bioethical committee, and the protocol of the study followed 
the principles of the Helsinki Declaration.
Statistical analysis
Firstly, we assessed the distribution of variables using the 
Kolmogorov–Smirnov test and checked the skewness and 
kurtosis, assuming that values < −2 or > 2 conform to a normal 
distribution [8]. Then, we analysed the sociodemographic and 
clinical data with Student’s t-test or Mann–Whitney U test (de-
pending on the distribution), as well as with chi-square test (in 
case of frequencies). Finally, for testing the causal inferences 
between the dependent (patients’ remission) and independent 
variables, we built a multiple logistic regression model with se-
lected potential factors affecting the patients’ state, adjusted for 
sex and age. All criteria were met and the model’s goodness of 
fit was analysed with the Hosmer-Lemeshow test. Calculations 
were performed using the Statistica 13.1 package. The level of 
statistical significance was determined at p < 0.05.
Results
530 adult patients were included in this study (mean age 
± standard deviation (SD): 36.1 ± 12.6 years; range: 18–84). 
Of these, 327 (61.7%) were female, and 364 (68.7%) had focal 
epilepsy. The average age at the onset of epilepsy was 18.6 
± 13.1 years. Twelve-month seizure freedom was achieved in 
246 (46.4%) patients. A definite cause of epilepsy was identi-
fied in 53.4% of the cases, with structural/infectious aetiology 
being the most common. In 80 (15.1 %) patients, intellectual 
disability was found. Table 1 sets out the clinical characteristics 
of the study group regarding age, sex, age at onset of epilepsy, 
type and aetiology of epilepsy, frequency of seizures, the num-
ber of currently used AEDs, and its dosage. More than half 
of the patients (292, 55.1%) were on monotherapy; the most 
Table 1. General characteristics of studied patients with epilepsy and 
current treatment of epilepsy
Variable
Female sex; n (%)
Age (years) mean (± SD) [range]
Age at onset of epilepsy (years); mean (± SD) 
[range]
Duration of epilepsy (years); mean (± SD) 
[range]
Aetiology of epilepsy
    Genetic/presumed genetic 
    Structural/infectious 
    Unknown
Type of epilepsy type; n (%)
    Generalised
    Focal
    Combined (generalised and focal)
    Unknown
Frequency of seizures; n (%)
    Remission
    No remission
Intellectual disability
Number of currently used AEDs; mean 
(range)
    Monotherapy; n (%)
    Polytherapy; n (%)
Number of drug trials
    Mean (±SD) [range]
    Median
The most commonly used AEDs (in mono-  
or polytherapy); n (%) and its mean daily 
dose (mg/day) [range]
    Levetiracetam 
 
    Valproic acid
 
    Lamotrigine
 
    Carbamazepine 
 
    Topiramate
327 (61.7%)
36.1 (± 12.6) [18–84]
18.6 (± 13.1) [1–72] 














3.4 (± 2.5) [1–17]
3
234 (44.1%) 1,992 
[500–4,500]
215 (40.6 %) 1,378 
[500–4,000]
147 (27.7%) 301 
[50–700]
72 (13.6%) 981 
[200–3,600]
54 (10.2%) 270 
[50–600]
AEDs — antiepileptic drugs; SD — standard deviation
commonly used AEDs were levetiracetam, valproate (VPA), 
and lamotrigine (LTG). 
A large majority (173, 72.7%) of the patients undergoing 
combination therapy were treated with two AEDs; 58 (24.4%) 
and seven (2.9%) patients were treated with three and 
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≥ 4 drugs, respectively. 228 (95.8%) patients on polytherapy 
were prescribed AEDs with differing MOAs, and 55 (23.1%) 
patients took a combination of VPA and LTG. Among the 
seizure-free patients, 191 (77.6%) took one AED. Of the 
65 patients on ≥ 3 drugs, only five (7.7%) achieved 12-month 
remission. Patients with persistent seizures were prescribed 
higher mean doses of AEDs than those in remission (Fig. 1). 
We included into univariate analysis age, gender, age at 
onset of epilepsy, aetiology of epilepsy, type of epilepsy, the 
presence of intellectual disability, AEDs treatment (mono- vs 
polytherapy), number of currently used AEDs, number of 
AEDs’ trials, and treatment with a VPA+ LTG combination. 
Due to multicolinearity with the type of epilepsy, we excluded 
aetiology of epilepsy from further analysis.
Table 2 sets out a comparison of clinical features and 
treatment parameters in patients in remission and in patients 
with persistent seizures. Seizure-free patients were younger, 
had a shorter duration of epilepsy, more frequently were on 
monotherapy, and suffered from generalised epilepsy. Intel-
lectual disability was less frequent in seizure-free patients. The 
number of prescribed AEDs and the number of previously 
tried AEDs was lower in this group.
Multivariate analysis revealed several independent predic-
tors of seizure freedom: younger age (odds ratio (OR) = 0.98; 
95% confidence interval (95%CI) = 0.95–0.99; p = 0.037), male 
sex (OR = 1.54; 95%CI = 1.00–2.40; p = 0.050), generalised 
epilepsy (OR = 1.61; 95%CI = 1.00–2.56; p = 0.052), lower 
number of prescribed AEDs (OR = 0.22; 95%CI = 0.10–0.47; 
p = 0.001), and taking a combination of VPA and LTG (OR 
= 2,51; 95%CI = 1.11–5.55; p = 0.024). The model explains 
28% of dependent variable’s variance and achieves a good fit.
Discussion
In a large cohort of patients treated at the university epilepsy 
clinic, the overall rate of 12-month seizure freedom was 46.4%. 
This percentage is much lower than that reported in the recently 
published longitudinal observational cohort study by Chen et 
al., where the rate of remission in patients with newly diagnosed 
epilepsy was as high as 63.7% [3]. This discrepancy may be partly 
explained by the fact that the majority of the patients treated in 
our clinic were referred by general practitioners or neurologists 
due to refractory epilepsy or AED-related side effects.
In logistic regression analysis, we found several inde-
pendent predictors of seizure freedom: younger age, male sex, 
generalised epilepsy, lower number of prescribed AEDs, and 
taking a combination of VPA and LTG.
In our study, similar to the study of Mäkinen et al., older 
age was associated negatively with remission [9]. This result 
may reflect the permanent pharmacoresistance of epilepsy. 
Male patients and subjects with generalised epilepsy had 
a higher probability of seizure freedom. These findings are 
Figure 1. Mean daily doses of antiepileptic drugs in patients with remission and persistent seizures. VPA — valproate; LEV — levetiracetam; 
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n % n % P-value
Gender
     Female 154 62.6 173 60.9 χ2 = 0.16 
P = 0.690
     Male 92 37.4 111 39.1
Epilepsy type
     Generalised 77 31.3 49 17.3 χ2 = 28.71a
P < 0.001     Focal 151 61.4 213 75
     Combined (generalised and focal) 1 0.4 14 4.9
     Unknown 17 6.9 8 2.8
Presence of intellectual disability 25 10.2 55 19.4 χ2 = 8.71 
P = 0.003
AEDs therapy
     Monotherapy 191 77.6 101 35.6 χ2 = 85.85 
P < 0.001
     Polytherapy 55 22.4 183 64.4
MOA in patients on polytherapy
     Different 55 100 173 94.5 χ2 = 1.88 
P = 0.171
     SCB 0 0 10 5.5
VPA+LTG
     Yes 15 6 30 11 χ2 = 3.38 
P = 0.066
     No 231 94 254 89
Mean (± SD) Median Mean (± SD) Median
Age (years) 34.1 (± 12.2) 31 37.9 (± 12.7) 36 T = −3.58 
P < 0.001
Age at onset of epilepsy (years) 19.2 (± 12.7) 17 18.1 (± 13.5) 16 T = 0.88 
P = 0.379
Duration of epilepsy (years) 14.7 (± 10.1) 13 19.7 (± 12.5) 18 T = −5.10 
P < 0.001
Number of AEDs 1 (± 0.5) 1 1.9 (± 0.8) 2 Z = −10.28 
P < 0.001
AED’s trial number 2.3 (± 1.47) 2 4.4 (± 2.7) 4 Z = −10.50 
P < 0.001
a Generalised epilepsy was more frequent in patients with remission (P < 0.001); focal and combined generalised and focal epilepsy were more frequent in patients without remission (P < 0.001). AEDs — antie-
pileptic drugs; MOA — mechanism of action; SCB — sodium channel blocker; SD — standard deviation
concordant with the results of Chen et al. [3]. The higher per-
centage of seizure-free males may be related to the decreasing 
usage of highly effective AEDs with teratogenic potential, such 
as VPA or topiramate, in women. Patients with generalised 
epilepsy were more likely to enter remission. Moreover, most 
patients with generalised epilepsy and persistent seizures 
had less disabling types of seizures, including myoclonic or 
absence. Genetic generalised epilepsies typically respond well 
to treatment [10, 11]. The probability of remission decreased 
substantially with the higher number of currently used and 
previously tried AEDs, which is in line with the results of 
previous studies [3, 12, 13]. Nevertheless, seizure freedom 
on polytherapy was achieved by a substantial proportion of 
patients (55; 22.4%), which is consistent with the findings of 
Stephen et al. [14]. 
Combining drugs with different MOAs is thought to be 
more successful in patients requiring polytherapy, although 
the clinical evidence in support of this strategy is very limited 
[15]. The clinical efficacy of pharmacodynamic synergism of 
VPA/LTG polytherapy was proved by Brodie and Yuen [16]. 
With regards to MOA, the vast majority (95.8%) of the patients 
on polytherapy were prescribed AEDs with a different MOA. 
This made a comparison of the efficacy of rational polyther-
apy with combining AEDs with the same MOA impossible. 
However, we found that the combination of VPA and LTG 
was an independent predictor of remission. This AED com-
bination appears to have synergistic therapeutic effects due 
to both pharmacokinetic and pharmacodynamic interactions 
[15–18]. In clinical practice, the concomitant use of VPA 
and LTG may pose a therapeutic challenge due to significant 
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pharmacokinetic interactions and the risk of LTG-related skin 
rash. VPA as a potent inhibitor of UDP-glucuronosyltrans-
ferase inhibits LTG metabolism with a marked prolongation 
of LTG half-life and a reduction of LTG dosage requirements 
in patients co-medicated with VPA. LTG administration may 
be associated with idiosyncratic skin and systemic adverse 
reactions, which are more frequent with fast increments in 
LTG dosage. The introduction of LTG in patients co-medicated 
with VPA should be undertaken with caution, using a lower 
starting dose and a slower pace of escalation [17, 18].
The mean doses for AEDs used in refractory patients were 
higher than those in seizure-free patients, a fact which poses 
a considerable risk of overtreatment in terms of unnecessary 
doses and side effects [19]. According to Mohanraj and Brodie, 
the majority of patients achieve remission with modest or moder-
ate daily doses, which accords with the results of our study [20].
Our study has some limitations. Firstly, we defined re-
mission as no seizures in the past ≥ 12 months [7]. However, 
patients may enter early or late remission, on or off medication. 
Early remission is not always followed by a lasting seizure-free 
period. Moreover, there are many prognostic factors of 
treatment response, such as aetiology, number of seizures at 
diagnosis, seizures during sleep, epileptiform abnormalities, 
abnormalities on neuroimaging, psychiatric comorbidity, med-
ication adherence, and previous episodes of status epilepticus, 
which we were not able to evaluate due to small sample size 
or lack of information [21–27]. 
Secondly, the studied cohort involved a limited sample size of 
adult patients followed up in the university epilepsy clinic; these 
may differ substantially from the general population of patients 
with epilepsy with regard to the frequency of seizures or use of 
polytherapy. Thirdly, this was a retrospective study and therefore 
some information may have been missed. Finally, many newer 
AEDs, such as eslicarbazepine, brivaracetam, perampanel, and 
zonisamide are not available or are not reimbursed in Poland, 
which makes comparisons to other studies more difficult.
Conclusions
The majority of patients with epilepsy achieve seizure 
freedom on monotherapy, and with their first or second AED. 
However, one in five patients may benefit from polytherapy. 
Thus, we hypothesise that a combination therapy comprising 
VPA and LTG may prove useful in pharmacoresistant cases.
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